MedPath

M.D. ANDERSON CANCER CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

Recruiting
Conditions
Tumors
First Posted Date
2023-02-17
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
300
Registration Number
NCT05733091
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer

Phase 1
Recruiting
Conditions
Colon Cancer
Colorectal Cancer
Interventions
First Posted Date
2023-02-10
Last Posted Date
2024-12-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
24
Registration Number
NCT05722327
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

First Posted Date
2023-02-08
Last Posted Date
2024-12-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT05717400
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Phase 2
Recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Nivolumab
Drug: Etigilimab
First Posted Date
2023-02-06
Last Posted Date
2024-07-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT05715216
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Randomized Trial Comparing a Ventilatory Strategy to Prevent Atelectasis Versus a Lateral Decubitus Strategy During Robotic Bronchoscopy (VESPA Vs. LADS Trial)

Not Applicable
Recruiting
Conditions
Pulmonary
Lung
Interventions
Procedure: Lateral Decubitus Strategy (LADS)
Procedure: Ventilatory Strategy To Prevent Atelectasis
First Posted Date
2023-02-06
Last Posted Date
2024-10-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT05714033
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC

Phase 2
Recruiting
Conditions
Spinal Disease
Interventions
Procedure: Spine Radiosurgery
Device: Magnetic Resonance imaging
Radiation: MR-LINAC
First Posted Date
2023-02-02
Last Posted Date
2024-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT05709782
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Phase 1
Recruiting
Conditions
Advanced Renal Cell Carcinoma
Advanced Mesothelioma
Advanced Osteosarcoma
Interventions
Drug: CAR.70/IL15-transduced CB-derived NK cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
First Posted Date
2023-01-30
Last Posted Date
2024-12-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT05703854
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Phase 2
Recruiting
Conditions
Melanoma (Skin)
Interventions
Drug: BMS-986213 (Relatlimab-Nivolumab FDC)
Drug: Nivolumab
Drug: Relatlimab
First Posted Date
2023-01-30
Last Posted Date
2024-10-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05704647
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Phase 1
Recruiting
Conditions
Lung Cancer
Interventions
First Posted Date
2023-01-30
Last Posted Date
2024-07-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
56
Registration Number
NCT05704634
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2
Recruiting
Conditions
Brain Metastases
Interventions
First Posted Date
2023-01-26
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
120
Registration Number
NCT05700721
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath